Cas 1010102-72-3,3-(tert-butyldiphenylsilyloxy)-2-(5-methoxypyrimidin-2-yl)furo[2,3-c]pyridine

1010102-72-3

Post Buying Request

Basic information

Product Name: 3-(tert-butyldiphenylsilyloxy)-2-(5-methoxypyrimidin-2-yl)furo[2,3-c]pyridine
Synonyms: 3-(tert-butyldiphenylsilyloxy)-2-(5-methoxypyrimidin-2-yl)furo[2,3-c]pyridine
CAS NO:1010102-72-3
Molecular Formula:
Molecular Weight: 481.626
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: 3-(tert-butyldiphenylsilyloxy)-2-(5-methoxypyrimidin-2-yl)furo[2,3-c]pyridine(CAS DataBase Reference)
NIST Chemistry Reference: 3-(tert-butyldiphenylsilyloxy)-2-(5-methoxypyrimidin-2-yl)furo[2,3-c]pyridine(1010102-72-3)
EPA Substance Registry System: 3-(tert-butyldiphenylsilyloxy)-2-(5-methoxypyrimidin-2-yl)furo[2,3-c]pyridine(1010102-72-3)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 1010102-72-3(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

1010102-72-3 Suppliers

Recommended suppliers

1010102-72-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1010102-72-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,1,0,1,0 and 2 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1010102-72:
(9*1)+(8*0)+(7*1)+(6*0)+(5*1)+(4*0)+(3*2)+(2*7)+(1*2)=43
43 % 10 = 3
So 1010102-72-3 is a valid CAS Registry Number.

1010102-72-3Upstream product

1010102-72-3Downstream Products

1010102-72-3Relevant academic research and scientific papers

RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF

-

Page/Page column 32, (2010/04/23)

Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 1010102-72-3